Association of C-Reactive Protein With Cardiovascular Disease Mortality According to Diabetes Status
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: C-reactive protein (CRP) is associated with the risk of cardiovascular disease (CVD); whether the effects are modified by diabetes status still is unclear. This study investigated these issues and assessed the added value of CRP to predictions. RESEARCH DESIGN AND METHODS: Participants were drawn from representative samples of adults living in England and Scotland. Cox proportional hazards regression models were used to relate baseline plasma CRP with all-cause and CVD mortality during follow-up in men and women with and without diabetes. The added value of CRP to the predictions was assessed through c-statistic comparison and relative integrated discrimination improvement. RESULTS: A total of 25,979 participants (4.9% with diabetes) were followed for a median of 93 months, during which period there were 2,767 deaths (957 from CVD). CRP (per SD loge) was associated with a 53% (95% CI 43–64) and 43% (38–49) higher risk of cardiovascular and all-cause mortality, respectively. These associations were log linear and did not differ according to diabetes status (both P ≥ 0.08 for interaction), sex, and other risk factors. Adding CRP to conventional risk factors improved predictions overall and separately by diabetes status but not for CVD mortality, although such improvements only were marginal based on several discrimination statistics. CONCLUSIONS: The association between CRP and CVD was similar across diabetes status, and the effects are broadly similar across levels of other conventional risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“elevated hsCRP has been found to be predictive of major adverse CV events and death in individuals with or without type 2 diabetes and/or previous CV events [35].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“The JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) has shown that CRPwas useful for targeting statin therapy in healthy individuals with normal-range LDL cholesterol (32).”
MethodPencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 2×
“The relative integrated discrimination improvement (RIDI%), which measures the percentage improvement in discrimination when an extra variable is added to a prediction model (16), was computed.”
MethodRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953 · cited 2×
“In addition, it has been demonstrated that CRP was stable enough for use in long-term predictions (3).”
Background(2010) · The Lancet · doi:10.1016/s0140-6736(09)61717-7 · Cited by 2,546 · cited 7×
“In theEmerging Risk Factors Collaboration (ERFC) overview,where statistical interactionwas tested, CRP was a similar determinant of coronary heart disease in participants with diabetes and those without (7).”
BackgroundMethodResultInfluentialCardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163 · cited 1×
“The incremental value of CRP was further assessed by refitting the Framingham Anderson general equation for the prediction of cardiovascular mortality (without electrocardiographic left ventricular hypertrophy, a missing predictor in our sample) data with and without CRP (19).”
MethodModelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432 · cited 1×
“The proportional hazards assumption was tested with the use of the cumulative sums of Martingale-based residuals methods (12) and found not to be violated.”
MethodGreenland, P. (2008) · Statistics in Medicine · doi:10.1002/sim.2976 · Cited by 1,300
Targeting C-reactive protein for the treatment of cardiovascular disease.
Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., et al. (2006) · Nature · doi:10.1038/nature04672 · Cited by 672 · cited 1×
“Therefore, CRP may not be a target for CVD prevention (2,30).”
BackgroundC Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) (2011) · BMJ · doi:10.1136/bmj.d548 · Cited by 642
Collett, D. (1994) · Modelling Survival Data in Medical Research · doi:10.1007/978-1-4899-3115-3_3 · Cited by 518
Czernichow, S., Kengne, A. ‐., Stamatakis, E., Hamer, M., & Batty, G. D. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00879.x · Cited by 470 · cited 1×
“studies comprising either Scottish health surveys (1998 and 2003) or the health surveys for England (1998 and 2003) (9).”
BackgroundSelf-citationEaston, D. F., Peto, J., & Babiker, A. G. A. G. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100703 · Cited by 433 · cited 1×
“3 mg/L (13), with 95% CIs in both analyses derived from the floating absolute-risk methods (14).”
BackgroundModelling Survival Data in Medical Research
(2004) · Technometrics · doi:10.1198/tech.2004.s817 · Cited by 430 · cited 1×
“We also calculated 1) the likelihood ratio x(2), which compares the adequacy of a model with covariates fitted to a set of data to that of the null model (without covariates) fitted to the same dataset; and 2) the Akaike information criterion (AIC), which allows for comparisons between models (nested or not); the smal…”
MethodMyers, G. L., Rifai, N., Tracy, R. P., Roberts, W. L., Alexander, R. W., Biasucci, L. M., Catravas, J. D., Cole, T. G., Cooper, G. R., Khan, B. V., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148980.87579.5e · Cited by 391
Modelling Survival Data in Medical Research (2nd ed.) (Book)
Cowles, M. K. (2004) · Quarterly Publications of the American Statistical Association · Cited by 369
C‐reactive protein and coronary heart disease: a critical review
Casas, J. P., Shah, T., Hingorani, A. D., Danesh, J., & Pepys, M. B. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02015.x · Cited by 366 · cited 1×
“Concentrations of CRP in the upper part of the distribution within the normal range and above are associated with the long-term risk of CVD and allcause mortality in different populations (6,7).”
BackgroundJager, A., van Hinsbergh, V. W. M., Kostense, P. J., Emeis, J. J., Yudkin, J. S., Nijpels, G., Dekker, J. M., Heine, R. J., Bouter, L. M., & Stehouwer, C. D. A. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.12.3071 · Cited by 288 · cited 3×
“In the Hoorn Study (20), it was suggested that the magnitude of the association of CRP with cardiovascular death was similar in participants with type 2 diabetes and those without.”
ResultInfluentialAssessment of Claims of Improved Prediction Beyond the Framingham Risk Score
Tzoulaki, I. (2009) · JAMA · doi:10.1001/jama.2009.1757 · Cited by 276 · cited 4×
“Results in the general population have been inconsistent, with some showing marginal to sizable improvement and others no added value at all (25,26).”
BackgroundMethodInfluentialRIDKER, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 270 · cited 1×
“It is expected that trials of specific CRP antagonists and low-dose methotrexate will clarify this in the future (31).”
BackgroundShah, T., Casas, J. P., Cooper, J. A., Tzoulaki, I., Sofat, R., McCormack, V., Smeeth, L., Deanfield, J. E., Lowe, G. D., Rumley, A., et al. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyn217 · Cited by 238 · cited 4×
“Results in the general population have been inconsistent, with some showing marginal to sizable improvement and others no added value at all (25,26).”
BackgroundMethodInfluentialPearson, T. A., Mensah, G. A., Hong, Y., & Smith, S. C. (2004) · Circulation · doi:10.1161/01.cir.0000148979.11121.6b · Cited by 206
Soinio, M., Marniemi, J., Laakso, M., Lehto, S., & Rönnemaa, T. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1700 · Cited by 186 · cited 1×
“Some have instead suggested that other cardiovascular risk factors that frequently displayed less favorable levels in people with diabetes compared with those without canmask the association between CRP and CVD and make it a less stronger determinant in people with diabetes (24).”
BackgroundC-reactive protein and myocardial infarction
Sakkinen, P., Abbott, R. D., Curb, J. D., Rodriguez, B. L., Yano, K., & Tracy, R. P. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00502-9 · Cited by 175 · cited 2×
“400 DIABETES CARE, VOLUME 35, FEBRUARY 2012 care.diabetesjournals.org (21), Honolulu Heart Program (22), and the study by Biasucci et al. (23), CRP was a significant predictor of CVD only among participants without diabetes, and point estimates, when provided, were lower in participants with diabetes but with a substa…”
BackgroundBest, L. G., Zhang, Y., Lee, E. T., Yeh, J.-L., Cowan, L., Palmieri, V., Roman, M., Devereux, R. B., Fabsitz, R. R., Tracy, R. P., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.489260 · Cited by 102
Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia–Pacific region
(2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280dce59e · Cited by 94
C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?
Hingorani, A. D., Shah, T., Casas, J. P., Humphries, S. E., & Talmud, P. J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.115923 · Cited by 70 · cited 1×
“Therefore, CRP may not be a target for CVD prevention (2,30).”
BackgroundCholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region
Asia Pacific Cohort Studies Collaboration (2007) · Diabetologia · doi:10.1007/s00125-007-0801-2 · Cited by 69
C-Reactive Protein and 5-Year Survival in Type 2 Diabetes
Bruno, G., Fornengo, P., Novelli, G., Panero, F., Perotto, M., Segre, O., Zucco, C., Deambrogio, P., Bargero, G., & Perin, P. C. (2009) · Diabetes · doi:10.2337/db08-0900 · Cited by 65
Fortmann, S. P., Ford, E., Criqui, M. H., Folsom, A. R., Harris, T. B., Hong, Y., Pearson, T. A., Siscovick, D., Vinicor, F., & Wilson, P. F. (2004) · Circulation · doi:10.1161/01.cir.0000148982.95775.bf · Cited by 55
Dent, T. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.021 · Cited by 54
Smoking, diabetes and cardiovascular diseases in men in the Asia Pacific region
Kengne, A. P., Nakamura, K., Barzi, F., Tai Hing, L. A. M., Huxley, R., Gu, D., Patel, A. A., Kim, H. C., & Woodward, M. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00028.x · Cited by 48
Self-citationQasim, A. N., Budharaju, V., Mehta, N. N., St Clair, C., Farouk, S., Braunstein, S., Schutta, M., Iqbal, N., Rader, D. J., & Reilly, M. P. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03879.x · Cited by 43
Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
Elliott, P. (2009) · JAMA · doi:10.1001/jama.2009.954 · Cited by 35 · cited 1×
“Based on available evidence (4,28,29), a causal role for CRP in CVD is less certain.”
BackgroundBiasucci, L. M., Liuzzo, G., Bona, R. D., Leo, M., Biasillo, G., Angiolillo, D. J., Abbate, A., Rizzello, V., Niccoli, G., Giubilato, S., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119156 · Cited by 33 · cited 1×
“(23), CRP was a significant predictor of CVD only among participants without diabetes, and point estimates, when provided, were lower in participants with diabetes but with a substantial overlap of the confidence interval about point estimates in those with and without diabetes (21–23).”
BackgroundC reactive protein and the risk of cardiovascular disease
Keavney, B. D. (2011) · BMJ · doi:10.1136/bmj.d144 · Cited by 18 · cited 2×
“C-reactive protein (CRP), an inflammatory biomarker, is one of the most well-documented emerging CVD risk factors (4,5).”
BackgroundHosmer (1997) · doi:10.1002/(sici)1097-0258(19970515)16:9<965::aid-sim509>3.0.co;2-o
Cited by
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.006 · Cited by 1,981
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
“The identification of potential pathways connecting inflammation to diabetes has produced growing interest in targeting inflammation to help prevent and control diabetes and related conditions, as well as improving risk stratification for diabetes by using inflammatory biomarkers as potential indexes.(23,24)”
BackgroundDiabetes Mellitus and Inflammation
Lontchi-Yimagou, E., Sobngwi, E., Matsha, T. E., & Kengne, A. P. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0375-y · Cited by 807
Self-citationCardiovascular risk assessment in patients with diabetes
Bertoluci, M. C., & Rocha, V. Z. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0225-1 · Cited by 255
Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes
Grossmann, V., Schmitt, V. H., Zeller, T., Panova-Noeva, M., Schulz, A., Laubert-Reh, D., Juenger, C., Schnabel, R. B., Abt, T. G. J., Laskowski, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-3008 · Cited by 257
Metadata
- Authors
- Kengne, A. P., Batty, G. D., Hamer, M., Stamatakis, E., & Czernichow, S.
- Affiliations
- NCRP for Cardiovascular and Metabolic Diseases, South African Medical Research Council and University of Cape Town, Cape Town, South Africa
- University College London (GB)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-01-16
- Volume
- 35
- Issue
- 2
- Pages
- 396-403
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3263864
- OpenAlex
- W2136901433
- Cited by
- 105
- References
- 40
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 5 · 2023: 5 · 2022: 11 · 2021: 8 · 2020: 13 · 2019: 8 · 2018: 4 · 2017: 6 · 2016: 12 · 2015: 10 · 2014: 7 · 2013: 7 · 2012: 3
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- C-reactive protein, cardiovascular mortality, diabetes mellitus, all-cause mortality, cardiovascular risk prediction, inflammation, sex differences
- MeSH terms
- Adult, Aged, C-Reactive Protein, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Male, Middle Aged, Prospective Studies, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.